Of clinical relevance, VE‐PTP inhibition is beneficial in disease models of retinopathy, diabetic nephropathy, glaucoma, hypertension, and metastasis (Goel et al, 2013; Shen et al, 2014; Carota et al, 2019; Li et al, 2020; Siragusa et al, 2021) and in human diabetic macular edema (Campochiaro et al, 2016). This evidence concerns the gene PTPRB and glaucoma.